Kidney & Blood Pressure Research, published by KARGER, is a premier open-access journal dedicated to the evolving fields of nephrology and cardiovascular medicine. Since its inception in 1978 and with a forward-looking scope extending to 2024, this journal plays a vital role in disseminating innovative research and clinical findings related to kidney health and blood pressure regulation. With an impressive 2023 Impact Factor and ranked in the second quartile (Q2) in both cardiology and nephrology categories, it is recognized as a significant resource among its peers, including a Scopus rank of #23 in Nephrology and #128 in Cardiology. The journal's commitment to open access since 2013 further ensures that cutting-edge research is readily available to the global scientific community. Based in Switzerland, the journal not only fosters academic collaboration but also addresses critical health challenges related to kidney function and hypertension. It is a crucial platform for researchers, healthcare professionals, and students alike, encouraging the ongoing dialogue and advancement of knowledge in these critical areas of health.

TRENDS IN CARDIOVASCULAR MEDICINE, published by Elsevier Science London, stands at the forefront of the cardiology field, with a commendable Q1 ranking in the category of Cardiology and Cardiovascular Medicine. Since its inception in 1991, this esteemed journal has provided a vital platform for disseminating cutting-edge research and innovative clinical practices, reflecting the dynamic developments in cardiovascular health. With an impact factor positioning it among the top 3% in its category, TRENDS IN CARDIOVASCULAR MEDICINE is essential reading for researchers, healthcare professionals, and students pursuing the latest advancements and evidence-based approaches in cardiology. Although this journal does not currently operate under an open-access model, its rich array of content encompasses a variety of topics from clinical studies to reviews, ensuring readers stay informed on the pivotal trends that shape cardiovascular medicine. This commitment to excellence underscores the journal's role as a premier resource for anyone dedicated to improving cardiovascular health.

Integrated Blood Pressure Control is a distinguished Open Access journal published by DOVE MEDICAL PRESS LTD in New Zealand, dedicated to advancing the field of cardiology and cardiovascular medicine as well as internal medicine. With its established timeline from 2009 to 2024, this journal has earned a commendable Q2 ranking in both its categories for 2023, reflecting its significant contribution to clinical research and practice. With an ISSN of 1178-7104, it provides a platform for high-quality, peer-reviewed articles that address the complexities of blood pressure management, aiming to improve patient outcomes and foster discussions among healthcare professionals. The journal's open-access model, implemented since 2008, ensures that research findings are readily available to all, promoting greater accessibility and dissemination of knowledge in this critical area of health. Researchers, professionals, and students alike are encouraged to engage with the latest findings and innovative practices published within this journal, which plays an essential role in shaping the future of blood pressure control and related medical fields.

Pregnancy Hypertension – An International Journal of Women's Cardiovascular Health, published by Elsevier Science Ltd, is a leading platform dedicated to advancing the understanding of cardiovascular health in women during pregnancy and postpartum periods. With an ISSN of 2210-7789, this esteemed journal has distinguished itself in the fields of Internal Medicine and Obstetrics and Gynecology, maintaining a remarkable Q2 ranking in Internal Medicine and a prestigious Q1 ranking in Obstetrics and Gynecology as of 2023. It is recognized for its high-quality research, which fits within the top quartile of its categories, and spans from 2010 to 2024, reflecting its ongoing contribution to critical advancements in women's cardiovascular health. The journal is accessible to a global audience of researchers, practitioners, and students, emphasizing its commitment to promoting open scholarly communication, although it currently operates under traditional access. The publication serves as a crucial resource for those seeking to enhance their knowledge and practices related to the unique cardiovascular challenges faced by women during pregnancy, thereby fostering informed clinical approaches and improved health outcomes.

Ophthalmology Glaucoma is a premier academic journal dedicated to advancing the understanding and management of glaucoma, a leading cause of irreversible blindness worldwide. Published by Elsevier, this journal covers a broad spectrum of topics within the field of ophthalmology, providing a platform for groundbreaking research and clinical insights. With an impressive impact factor that places it in the Q1 category of ophthalmology journals, and a commendable Scopus ranking of 29 out of 137, Ophthalmology Glaucoma is recognized for its rigorous peer-review process and high-quality publications. Since its inception in 2018, the journal has focused on disseminating innovative findings and treatment modalities to enhance patient care and outcomes. Researchers, clinicians, and students are encouraged to explore the Open Access options available, promoting wider accessibility to critical scientific knowledge. By staying at the forefront of ophthalmic research, Ophthalmology Glaucoma plays an essential role in shaping practices and policies that improve eye health globally.

Clinical and Experimental Hypertension, published by Taylor & Francis Inc, is a crucial resource in the fields of internal medicine and physiology. With its inaugural publication dating back to 1978, this esteemed journal has successfully merged decades of research, providing a platform for the latest advancements in hypertension studies. Operating without an open access model, it is configured to serve a specialized audience of researchers, clinicians, and students who are dedicated to exploring innovative treatment modalities and understanding the complexities of hypertensive diseases. Ranked in the Q3 category in both Internal Medicine and Physiology, this journal accomplishes a commendable standing in the academic community, exemplified by its Scopus rankings which position it within the median percentile range in its field. By disseminating high-quality research and fostering scientific dialogue, Clinical and Experimental Hypertension plays a pivotal role in shaping contemporary understanding and clinical practices concerning hypertension management.

American Journal of Hypertension, published by Oxford University Press, is a leading peer-reviewed journal dedicated to the field of hypertension and cardiovascular health. With an ISSN of 0895-7061 and an E-ISSN of 1941-7225, this prestigious journal has been providing researchers and clinicians with significant advancements in hypertension research since its inception in 1954, with a continued focus on innovative studies through 2024. Ranked Q2 in Internal Medicine and positioned within the top 22% of its category according to Scopus, it is a vital resource for those involved in clinical practice and research aimed at understanding and managing hypertension. The journal disseminates pivotal findings, treatment updates, and guideline recommendations that contribute to improved patient care globally. Accessible solely through subscription, the American Journal of Hypertension is essential reading for professionals committed to enhancing cardiovascular health outcomes.

Primary Care Diabetes is a leading journal published by ELSEVIER SCI LTD, focusing on the intersection of diabetes care, endocrinology, and family medicine. Since its inception in 2007, the journal has made significant contributions to the field, achieving notable rankings in various categories, such as Q2 in Endocrinology, Diabetes and Metabolism, Q1 in Family Practice, and Q2 in Internal Medicine, as well as Nutrition and Dietetics for 2023. With an ISSN of 1751-9918 and an E-ISSN of 1878-0210, it serves as an essential resource for researchers, healthcare professionals, and students dedicated to advancing knowledge and practice in primary diabetes care. The journal's strong Scopus rankings reflect its commitment to publish high-quality research, fostering clinical practice improvements and enhanced patient outcomes. Although not open access, its articles are pivotal for anyone looking to stay ahead in the dynamic and vital domain of diabetes management.

International Journal of Cardiology Cardiovascular Risk and Prevention is a distinguished Open Access journal published by ELSEVIER, dedicated to advancing research in the realms of cardiology and cardiovascular medicine. With an ISSN of 2772-4875 and based in the Netherlands, this journal has rapidly established itself as a critical resource for academics and practitioners since its inception in 2021. The journal currently holds a respectable impact factor and occupies the Q2 quartile in both Cardiology and Cardiovascular Medicine and Internal Medicine categories, reflecting its commitment to sharing high-quality research. Researchers can take advantage of its open-access model, ensuring that cutting-edge findings are freely available to a global audience. The journal not only covers innovative studies on cardiovascular risk factors and prevention strategies but also aims to facilitate interdisciplinary collaboration. With an ongoing trajectory from 2021 to 2024, the International Journal of Cardiology Cardiovascular Risk and Prevention is poised to remain a pivotal platform for dialogue and discovery in the evolving landscape of cardiovascular health.

The Journal of Asthma and Allergy, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing research in the fields of immunology, allergy, and pulmonary medicine. Since its inception in 2008, this journal has provided a vital platform for disseminating high-quality, peer-reviewed research that explores the complexities of asthma and allergy, allowing researchers, professionals, and students to access critical insights without subscription barriers. With an impressive impact factor reflected in its 2023 quartile rankings (Q2) in both Immunology and Allergy, as well as Pulmonary and Respiratory Medicine, the journal stands as a significant contributor to the scientific community, promoting innovative findings that support clinical practice and patient care. Based in New Zealand, the Journal of Asthma and Allergy continues to be at the forefront of research, from its dedication to publishing cutting-edge studies to fostering an inclusive academic discourse that spans the globe. Access to relevant articles is available online, ensuring that all stakeholders in these fields can stay informed and engaged.